Our Pricing

Cheapest Place for Mounjaro - Lowest UK Prices at Cured Pharmacy

Published on: June 03, 2026

Finding the cheapest place for Mounjaro UK doesn't mean compromising on quality or safety. At Cured Pharmacy, we offer genuine UK-licensed Mounjaro (tirzepatide) pens from £124.99 with transparent upfront pricing, free clinical consultations with UK prescribers, and discreet next-day delivery across the UK.

Why Mounjaro Costs Vary Across UK Pharmacies

Mounjaro pricing in the UK varies significantly between providers due to differences in operational costs, consultation fees, and dispensing models. Some pharmacies bundle hidden fees into their service, while others advertise low prices but add consultation charges at checkout. At Cured Pharmacy, our £124.99 starting price includes your clinical assessment by a UK-registered prescriber, with no hidden charges or subscription requirements.

The cheapest place for Mounjaro UK will always be a registered pharmacy operating within MHRA and GPhC guidelines. Unregulated online sellers advertising unusually low prices often supply counterfeit or unlicensed products that pose serious health risks [1]. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), ensures every Mounjaro pen dispensed meets UK pharmaceutical standards and comes directly from licensed wholesalers.

How Mounjaro (Tirzepatide) Works for Weight Loss

Mounjaro works by mimicking natural gut hormones that signal fullness to the brain, slow gastric emptying, and improve insulin sensitivity. Patients typically report reduced appetite within the first week of treatment, with progressive weight loss occurring over subsequent months as the dose is gradually increased under prescriber supervision.

The medication is administered as a once-weekly subcutaneous injection using the KwikPen device. Each pen contains a single pre-measured dose, and the injection takes less than 30 seconds to complete. Your UK prescriber will determine your starting dose—usually 2.5mg for the first four weeks—before titrating upwards based on your tolerance and weight loss progress [3].

Dual-Action Mechanism

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. Unlike single-pathway treatments, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing enhanced effects on appetite regulation, insulin secretion, and energy expenditure.

In the landmark SURPASS-2 trial, participants receiving the 15mg maintenance dose achieved an average body weight reduction of 22.5% over 72 weeks—significantly superior to semaglutide comparators [1][2]. The dual mechanism also demonstrated better glycaemic control in patients with type 2 diabetes, though Mounjaro is now licensed for weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities [3].

Mounjaro Dosing Schedule and Treatment Duration

Treatment duration varies by individual. In clinical practice, most patients continue Mounjaro for 12-18 months to achieve and consolidate their weight loss goals. Some may require longer-term treatment to maintain weight reduction, particularly if they have significant metabolic comorbidities. Your prescriber will review your progress every 12 weeks and adjust your treatment plan accordingly.

It's important to note that Mounjaro is not a standalone solution—clinical trials combined the medication with lifestyle interventions including reduced-calorie diets and increased physical activity [1][3]. Patients who engage with structured weight management programmes alongside Mounjaro treatment achieve superior long-term outcomes compared to medication alone.

Standard Titration Protocol

UK prescribers follow a structured dose escalation schedule to minimise gastrointestinal side effects whilst optimising weight loss outcomes. The typical protocol begins with 2.5mg weekly for four weeks, increasing to 5mg for four weeks, then 7.5mg, 10mg, 12.5mg, and finally 15mg as the maintenance dose [3]. Not all patients require the maximum dose—your prescriber will assess your response at each stage and may maintain you on a lower dose if you're achieving satisfactory results with minimal side effects.

Clinical trials demonstrate that gradual titration significantly reduces the incidence of nausea, vomiting, and diarrhoea compared to starting at higher doses [1]. Most patients reach their maintenance dose within 20-24 weeks, at which point weight loss continues for up to 72 weeks or longer with sustained treatment [2].

Comparing Mounjaro to Other UK Weight Loss Treatments

The UK market now offers several prescription weight loss medications, each with distinct mechanisms, efficacy profiles, and cost considerations. Mounjaro represents the latest generation of GLP-1 receptor agonist therapy, delivering superior weight loss outcomes compared to earlier options in head-to-head clinical trials [2][4].

Wegovy (semaglutide) is the most commonly prescribed alternative, using a single GLP-1 pathway to achieve an average 15% body weight reduction over 68 weeks in the STEP-1 trial [4]. Whilst effective, it produces less weight loss than Mounjaro's dual-action mechanism. Saxenda (liraglutide) requires daily injections and typically achieves 8-10% weight reduction, making it suitable for patients preferring smaller, more gradual changes [5].

Oral medications like Orlistat and Mysimba work through entirely different mechanisms. Orlistat blocks dietary fat absorption and produces modest weight loss of 3-5% when combined with a reduced-fat diet [6]. Mysimba combines naltrexone and bupropion to reduce appetite and cravings, achieving approximately 5-9% weight reduction in clinical trials [7]. Neither oral option matches the efficacy of injectable GLP-1 therapies, but they may suit patients who prefer tablets or have contraindications to injectable treatments.

Who Can Use Mounjaro in the UK

Your UK prescriber will review your full medical history, current medications, and any previous weight loss attempts before determining whether Mounjaro is appropriate. Patients with a history of pancreatitis, severe renal impairment, or diabetic retinopathy require careful assessment and monitoring throughout treatment [3].

Age is also a consideration—Mounjaro is licensed for adults aged 18 and over, with limited safety data in patients over 75 years. Your prescriber may recommend alternative treatments if you fall outside the typical age range or have multiple complex comorbidities that require specialist endocrinology input.

Eligibility Criteria

Mounjaro is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or above, or 27 kg/m² or above in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea [3]. Your prescriber will calculate your BMI during the consultation and assess whether you meet the clinical criteria for treatment.

Certain medical conditions preclude Mounjaro use. The medication is contraindicated in patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastroparesis [3]. Pregnant or breastfeeding women should not use Mounjaro, and women of childbearing potential must use effective contraception during treatment and for at least two months after discontinuation.

How to Order Mounjaro from Cured Pharmacy

Our pricing is transparent from the outset—the £124.99 starting price you see includes your clinical consultation, prescription, and first supply of Mounjaro. There are no hidden consultation fees, subscription charges, or mandatory follow-up costs. You'll receive clear guidance on injection technique, dose escalation timing, and how to reorder your next supply when needed.

If the prescriber determines that Mounjaro is not clinically appropriate for you, they may recommend an alternative weight loss treatment from our range or advise you to discuss options with your GP. We never dispense prescription medications without a valid clinical assessment, in line with our GPhC registration requirements (9012511) and our commitment to patient safety.

Simple Three-Step Process

Ordering Mounjaro from Cured Pharmacy takes under five minutes. First, complete our free online consultation form, which asks about your weight history, medical conditions, current medications, and weight loss goals. This clinical questionnaire is reviewed by a UK-registered prescriber who will assess your suitability for Mounjaro based on MHRA licensing criteria and clinical guidelines [3].

If approved, your prescription is issued electronically and sent directly to our dispensary. We source all Mounjaro pens from UK-licensed wholesalers and conduct rigorous quality checks before dispatch. Your medication is packaged in plain, discreet boxes with no external pharmacy branding, and delivered via tracked courier within 24 hours to addresses across England, Scotland, Wales, and Northern Ireland.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. UK Medicines Information. Retrieved from https://www.medicines.org.uk/emc/product/14443 [accessed 13 August 2026]
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
5. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
6. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
7. Greenway, F. L., Fujioka, K., Plodkowski, R. A., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595–605. https://doi.org/10.1016/S0140-6736(10)60888-4 [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss outcomes vary between individuals and depend on adherence to treatment and lifestyle modifications.